Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Analysis
  • Published:

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Nature Medicine volume 29, pages 1867–1876 (2023)Cite this article

Subjects

Abstract

Glomerular filtration rate (GFR) decline is causally associated with kidney failure and is a candidate surrogate endpoint for clinical trials of chronic kidney disease (CKD) progression. Analyses across a diverse spectrum of interventions and populations is required for acceptance of GFR decline as an endpoint. In an analysis of individual participant data, for each of 66 studies (total of 186,312 participants), we estimated treatment effects on the total GFR slope, computed from baseline to 3 years, and chronic slope, starting at 3 months after randomization, and on the clinical endpoint (doubling of serum creatinine, GFR < 15 ml min−1 per 1.73 m2 or kidney failure with replacement therapy). We used a Bayesian mixed-effects meta-regression model to relate treatment effects on GFR slope with those on the clinical endpoint across all studies and by disease groups (diabetes, glomerular diseases, CKD or cardiovascular diseases). Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median coefficient of determination (R2) = 0.97 (95% Bayesian credible interval (BCI) 0.82–1.00)) and moderately associated with those on chronic slope (R2 = 0.55 (95% BCI 0.25–0.77)). There was no evidence of heterogeneity across disease. Our results support the use of total slope as a primary endpoint for clinical trials of CKD progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Treatment effect on 3-year total slope, chronic slope and clinical endpoint, overall and by disease group.
Fig. 2: Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the clinical endpoint.
Fig. 3: Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the clinical endpoint by disease groups.

Similar content being viewed by others

Data availability

All data used in the analysis were obtained by the CKD-EPI Clinical Trials (CT) group through third parties. Data use agreements prohibit CKD-EPI CT from sharing data with parties external to the agreement. See Supplementary Table 1 for the identity of third party providers. The following datasets can be requested through data-sharing platforms: Vivli: CANVAS (NCT01032629), CANVAS-R (NCT01989754), CREDENCE (NCT02065791), EMPA-REG Outcome (NCT01131676), EXAMINE (NCT00968708), Harmony Outcome (NCT02465515) and FIDELIO-DKD (NCT02540993); NIDDK: AASK (NCT04364139), FSGS/FONT (NCT00135811), HALT-PKD Study A and Study B (NCT00283686) and MDRD (NCT03202914); NHLBI BioLINCC: TOPCAT (NCT00094302) and SPRINT (NCT01206062); Clinical Study Data Request: PARADIGM-HF (NCT01035255) and ACCOMPLISH (NCT00170950); and sponsors’ website: LEADER (NCT01179048).

Code availability

The statistical code used for the primary analysis can be found at https://github.com/UofUEpiBio/ckdepict.

References

  1. Cockwell, P. & Fisher, L. A. The global burden of chronic kidney disease. Lancet 395, 662–664 (2020).

    PubMed  Google Scholar 

  2. Levey, A. S. et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 64, 821–835 (2014).

    PubMed  Google Scholar 

  3. Schievink, B. et al. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes. Metab. 18, 64–71 (2016).

    CAS  PubMed  Google Scholar 

  4. Grams, M. E. et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J. Am. Soc. Nephrol. 30, 1746–1755 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).

    Google Scholar 

  6. Gutierrez, O. M. et al. Association of estimated GFR calculated using race-free equations with kidney failure and mortality by black vs non-black race. JAMA 327, 2306–2316 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518–2531 (2014).

    PubMed  PubMed Central  Google Scholar 

  8. Inker, L. A. et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J. Am. Soc. Nephrol. 30, 1735–1745 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Atrasentan in Patients With IgA Nephropathy (ALIGN). US National Library of Medicine. NCT04573478

  10. Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy. US National Library of Medicine. NCT03608033

  11. Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard). US National Library of Medicine. NCT03643965

  12. Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). US National Library of Medicine. NCT04578834

  13. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT). US National Library of Medicine. NCT04578834

  14. A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). US National Library of Medicine. NCT05047263

  15. Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417–2428 (2008).

    CAS  PubMed  Google Scholar 

  16. Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N. Engl. J. Med. 383, 1436–1446 (2020).

    CAS  PubMed  Google Scholar 

  17. Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).

    CAS  PubMed  Google Scholar 

  18. Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 382, 2504–2513 (2020).

    CAS  PubMed  Google Scholar 

  19. Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

    CAS  PubMed  Google Scholar 

  20. Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018).

    CAS  PubMed  Google Scholar 

  21. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 6, 691–704 (2018).

    CAS  PubMed  Google Scholar 

  22. Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).

    CAS  PubMed  Google Scholar 

  23. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

    CAS  PubMed  Google Scholar 

  24. Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322, 1155–1166 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Rosenstock, J. et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69–79 (2019).

    CAS  PubMed  Google Scholar 

  26. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).

    PubMed Central  Google Scholar 

  27. Zannad, F. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385, 2067–2076 (2015).

    CAS  PubMed  Google Scholar 

  28. Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).

    PubMed  Google Scholar 

  29. Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–1392 (2014).

    CAS  PubMed  Google Scholar 

  30. McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).

    PubMed  Google Scholar 

  31. Gipson, D. S. et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 80, 868–878 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).

    CAS  PubMed  Google Scholar 

  33. McMurray, J. J. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767–771 (2003).

    CAS  PubMed  Google Scholar 

  34. Inker, L. A. et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am. J. Kidney Dis. 64, 848–859 (2014).

    PubMed  Google Scholar 

  35. Higgins, J. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions (Cochrane Collaboration, 2011).

  36. Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128–139 (2019).

    CAS  PubMed  Google Scholar 

  37. Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

    CAS  PubMed  Google Scholar 

  39. Neuen, B. L. et al. Acute treatment effects on GFR in randomized clinical trials of kidney disease progression. J. Am. Soc. Nephrol. 33, 291–303 (2022).

    PubMed  PubMed Central  Google Scholar 

  40. Vonesh, E. et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat. Med. 38, 4218–4239 (2019).

    PubMed  Google Scholar 

  41. Stan Development Team. RStan: the R interface to Stan. https://cran.r-project.org/web/packages/rstan/vignettes/rstan.html (2023).

  42. Levey, A. S. et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84–104 (2020).

    CAS  PubMed  Google Scholar 

  43. Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern. Med. 175, 1389–1398 (2015).

    PubMed  Google Scholar 

  44. Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M. & Liew, D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin. Ther. 31, 236–244 (2009).

    CAS  PubMed  Google Scholar 

  45. Collier, W. et al. Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD. Clin. J. Am. Soc. Nephrol. 18, 183–192 (2023).

    PubMed  Google Scholar 

  46. Greene, T. et al. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J. Am. Soc. Nephrol. 30, 1756–1769 (2019).

    PubMed  PubMed Central  Google Scholar 

  47. Levey, A. S., Coresh, J., Tighiouart, H., Greene, T. & Inker, L. A. Measured and estimated glomerular filtration rate: current status and future directions. Nat. Rev. Nephrol. 16, 51–64 (2020).

    PubMed  Google Scholar 

  48. Inker, L. A. et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737–1749 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Pottel, H. et al. Cystatin C-based equation to estimate GFR without the inclusion of race and sex. N. Engl. J. Med. 388, 333–343 (2023).

    CAS  PubMed  Google Scholar 

  50. Joffe, M. M. & Greene, T. Related causal frameworks for surrogate outcomes. Biometrics 65, 530–538 (2009).

    PubMed  Google Scholar 

  51. Daniels, M. J. & Hughes, M. D. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med. 16, 1965–1982 (1997).

    CAS  PubMed  Google Scholar 

  52. Burzykowski, T. & Buyse, M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm. Stat. 5, 173–186 (2006).

    PubMed  Google Scholar 

  53. Burzykowski, T., Molenberghs, G. & Buyse, M. (eds). The Evaluation of Surrogate Endpoints (Springer, 2005).

  54. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

    CAS  PubMed  Google Scholar 

  55. Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421–2431 (2002).

    CAS  PubMed  Google Scholar 

  56. Klahr, S. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330, 877–884 (1994).

    CAS  PubMed  Google Scholar 

  57. Estacio, R. O., Jeffers, B. W., Gifford, N. & Schrier, R. W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23, B54–B64 (2000).

    PubMed  Google Scholar 

  58. Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267–2276 (2014).

    PubMed  PubMed Central  Google Scholar 

  59. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).

    PubMed  PubMed Central  Google Scholar 

  60. Skali, H. et al. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am. Heart J. 162, 548–554 (2011).

    PubMed  Google Scholar 

  61. Vonesh, E. F. & Greene, T. Biased estimation with shared parameter models in the presence of competing dropout mechanisms. Biometrics 78, 399–406 (2022).

    PubMed  Google Scholar 

  62. Vonesh, E. F., Greene, T. & Schluchter, M. D. Shared parameter models for the joint analysis of longitudinal data and event times. Stat. Med. 25, 143–163 (2006).

    PubMed  Google Scholar 

  63. Rizopoulos, D. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R (Chapman and Hall/CRC, 2012).

  64. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36, 1–48 (2010).

    Google Scholar 

Download references

Acknowledgements

We thank the National Kidney Foundation (NKF) and its sponsors for funding this research. The NKF received consortium support from the following companies: AstraZeneca, Bayer, Boehringer Ingelheim, Cerium Pharma, Chinook, CSL Behring, Janssen, Novartis, NovoNordisk, ProKidney and Travere. This work also received support from the Utah Study Design and Biostatistics Center, with funding in part from the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR002538. The support and resources from the Center for High Performance Computing at the University of Utah are also gratefully acknowledged. We thank all investigators, study teams and participants of the studies included in the meta-analysis (Protocol). This analysis includes SPRINT and TOPCAT research materials obtained from the National Heart, Lung and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of SPRINT or TOPCAT or the NHLBI. The FSGS/FONT trial, HALT-PKD Study A and HALT-PKD Study B were conducted by the investigators of the respective studies and were supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from these studies reported here were supplied by the NIDDK Central Repository. This paper does not necessarily reflect the opinions or views of these studies, the NIDDK Central Repository or the NIDDK. We are grateful for data from AstraZeneca, Bayer AG, Boehringer Ingelheim, GlaxoSmithKline (made available through Vivli, Inc.), Novartis (made available through a clinical study data request (CSDR)), Novo Nordisk A/S and Takeda (made available through Vivli, Inc.). Vivli and CSDR have not contributed to or approved, and are not in any way responsible for, the contents of this publication.

Author information

Authors and Affiliations

  1. Division of Nephrology, Tufts Medical Center, Boston, MA, USA

    Lesley A. Inker, Shiyuan Miao, Juhi Chaudhari & Ronald D. Perrone

  2. Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA

    Willem Collier, Tom Greene & Benjamin Haaland

  3. Division of Nephrology, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY, USA

    Gerald B. Appel & Pietro Canetta

  4. George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia

    Sunil V. Badve, Brendon L. Neuen, Mark Woodward, John Chalmers, Bruce Neal, Vlado Perkovic, David Johnson & Meg Jardine

  5. Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain

    Fernando Caravaca-Fontán, Hernando Trujillo, Teresa Cavero & Angel Sevillano

  6. Department of Nephrology and Dialysis, Sant’Anna Hospital, ASST Lariana, Como, Italy

    Lucia Del Vecchio

  7. Division of Nephrology, RWTH Aachen University, Aachen, Germany

    Jürgen Floege & Thomas Rauen

  8. Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Marian Goicoechea, Eduardo Verde, Ursula Verdalles & David Arroyo

  9. Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

    William G. Herrington

  10. Nakayamadera Imai Clinic, Takarazuka, Japan

    Enyu Imai

  11. Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore

    Tazeen H. Jafar

  12. Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA

    Julia B. Lewis & Jamie Dwyer

  13. Division of Nephrology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China

    Philip K. T. Li, Kai-Ming Chow, Cheuk-Chun Szeto & Chi-Bon Leung

  14. Department of Nephrology, AZ Delta, Roeselare, Belgium

    Bart D. Maes

  15. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy

    Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna & Fabiola Carrara

  16. Renal, Dialysis and Transplant Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy

    Francesco P. Schena & Carlo Manno

  17. Renal Research Unit, Comprehensive Heart Failure Center, Department of Clinical Research and Epidemiology, University of Würzburg, Würzburg, Germany

    Christoph Wanner

  18. Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands

    Jack F. M. Wetzels

  19. George Institute for Global Health, School of Public Health, Imperial College London, London, UK

    Mark Woodward

  20. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Hiddo J. L. Heerspink

  21. Denver Health, Denver, CO, USA

    Raymond O. Estacio, Rebecca Hanratty, Di Xie & Fan Fan Hou

  22. Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada

    Brendan Barrett

  23. Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA

    Kenneth W. Mahaffey

  24. Boehringer Ingelheim International, Ingelheim, Germany

    Maximilian von Eynatten

  25. Section of Nephrology, University of Chicago School of Medicine, Chicago, IL, USA

    Arlene Chapman

  26. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    Vicente Torres

  27. Department of Medicine, Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA

    Alan Yu

  28. Division of Diseases and Hypertension, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA

    Godela Brosnahan

  29. Department of Nephrology Dialysis and Renal Transplantation, Alessandro Manzoni Hospital, Lecco, Italy

    Thierry Hannedouche, Giuseppe Maschio, Francesco Locatelli, Simeone Andrulli, Claudio Pozzi & Donatella Casartelli

  30. Cleveland Clinic Foundation, Cleveland, OH, USA

    Marc A. Pohl

  31. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    Itamar Raz

  32. Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA, USA

    Lawrence G. Hunsicker

  33. Department of Nephrology, Heilig Hartziekenhuis Roeselare-Menen, Roeselare, Belgium

    An Vanacker

  34. Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

    Thomas Malfait

  35. Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands

    Peter J. Blankestijn & Arjan van Zuilen

  36. Daiichi Sankyo, Tokyo, Japan

    Fumiaki Kobayashi

  37. Department of Medicine, Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    Hirofumi Makino

  38. Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China

    Juliana C. N. Chan

  39. Department of Nephrology, Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, Madrid, Spain

    Manuel Praga

  40. Merck & Co., Inc., Merck Research Laboratories, Upper Gwynedd, North Wales, PA, USA

    William F. Keane

  41. Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

    Richard Haynes, William G. Herrington, Colin Baigent & Martin Landray

  42. Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany

    Claudia Seikrit

  43. Department of Medical Statistics, RWTH Aachen University, Aachen, Germany

    Stefanie Wied

  44. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA

    Robert D. Toto

  45. Departments of Nephrology, University of Groningen, Groningen, The Netherlands

    Paul E. de Jong

  46. Department of Nephrology, St. Donato Hospital, Arezzo, Italy

    Mauro Saddelli

Authors
  1. Lesley A. Inker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Willem Collier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tom Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shiyuan Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juhi Chaudhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerald B. Appel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sunil V. Badve
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fernando Caravaca-Fontán
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lucia Del Vecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jürgen Floege
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marian Goicoechea
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Benjamin Haaland
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. William G. Herrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Enyu Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tazeen H. Jafar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Julia B. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Philip K. T. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Bart D. Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Brendon L. Neuen
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Ronald D. Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Giuseppe Remuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Francesco P. Schena
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Christoph Wanner
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Jack F. M. Wetzels
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Mark Woodward
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Hiddo J. L. Heerspink
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the CKD-EPI Clinical Trials Consortium

  • Raymond O. Estacio
  • , Rebecca Hanratty
  • , John Chalmers
  • , Pietro Canetta
  • , Brendan Barrett
  • , Bruce Neal
  • , Vlado Perkovic
  • , Kenneth W. Mahaffey
  • , David Johnson
  • , Meg Jardine
  • , Maximilian von Eynatten
  • , Eduardo Verde
  • , Ursula Verdalles
  • , David Arroyo
  • , Arlene Chapman
  • , Vicente Torres
  • , Alan Yu
  • , Godela Brosnahan
  • , Thierry Hannedouche
  • , Kai-Ming Chow
  • , Cheuk-Chun Szeto
  • , Chi-Bon Leung
  • , Di Xie
  • , Fan Fan Hou
  • , Jamie Dwyer
  • , Marc A. Pohl
  • , Itamar Raz
  • , Lawrence G. Hunsicker
  • , An Vanacker
  • , Thomas Malfait
  • , Giuseppe Maschio
  • , Francesco Locatelli
  • , Peter J. Blankestijn
  • , Arjan van Zuilen
  • , Fumiaki Kobayashi
  • , Hirofumi Makino
  • , Juliana C. N. Chan
  • , Simeone Andrulli
  • , Claudio Pozzi
  • , Donatella Casartelli
  • , Manuel Praga
  • , Hernando Trujillo
  • , Teresa Cavero
  • , Angel Sevillano
  • , Piero Ruggenenti
  • , Annalisa Perna
  • , Fabiola Carrara
  • , William F. Keane
  • , Carlo Manno
  • , Richard Haynes
  • , William G. Herrington
  • , Colin Baigent
  • , Martin Landray
  • , Thomas Rauen
  • , Claudia Seikrit
  • , Stefanie Wied
  • , Robert D. Toto
  • , Paul E. de Jong
  •  & Mauro Saddelli

Contributions

L.A.I., T.G. and H.J.H.L. conceived and designed the study. L.A.I., H.J.L.H. and J.C. conducted the literature search and study screening. G.B.A., S.V.B., F.C.-F., L.D.V., J.F., M.G., W.G.H., E.I., T.H.J., J.B.L., P.K.T.L., B.D.M., B.L.N., R.D.P., G.R., F.P.S., C.W., J.F.M.W. and M.W. collected data in the included studies. W.C., T.G., S.M. and J.C. analyzed the data. L.A.I., W.C., T.G., H.J.L.H. and B.H. wrote the first draft of the manuscript. All authors contributed to the interpretation of the data, provided critical feedback on paper drafts and approved the final draft.

Corresponding author

Correspondence to Lesley A. Inker.

Ethics declarations

Competing interests

L.A.I. reports funding from National Institutes of Health (NIH), National Kidney Foundation (NKF), Omeros, Chinnocks, and Reata Pharmaceuticals for research and contracts to Tufts Medical Center; consulting agreements to Tufts Medical Center with Tricida; and consulting agreements with Diamerix. W.H.C. reports funding from the NKF to his institute for his graduate research assistantship. T.G. reports grant support from the NKF, Janssen Pharmaceuticals, Durect Corporation and Pfizer and statistical consulting from AstraZeneca, CSL and Boehringer Ingleheim. B.H. consults for the NKF, Proxima Clinical Research, Value Analytics Health and Guidepoint Global. G.B.A. reports funding for research studies through Columbia University, Calliditas, Travere, Novartis, Equillium, Roche, Sanofi, Reata, Apellis, Nephronet, Goldfinch and Vertex; consultations for Sanofi-Genzyme, Roche/Genetech, Apellis, Novartis, Travere, Calliditas, Glaxo and Aurinia; and speaker’s honoraria from GlaxoSmithKline and Aurinia, both on lupus nephritis. S.V.B. reports funding from the National Health and Medical Research Council of Australia; has served on the advisory boards of Bayer, AstraZeneca and Vifor Pharma; and has received speaker’s honoraria from Bayer, AstraZeneca, Pfizer and Vifor Pharma, all fees paid to the George Institute for Global Health. L.D.V. was an advisory board member for Travere. L.D.V. is also National Leader for the PROTECT Study and the VISIONARY study. J.F. reports lecture and consulting honoraria from Alynlam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, Fresenius, Novartis, Omeros, Travere and Vifor and is a member of the data safety monitoring board in trials for Novo Nordisk and Visterra. W.G.H. reports personal funding from the UK Medical Research Council (MC_UU_00017/3) and Kidney Research UK (MR/R007764/1) and grants to the University of Oxford from Boehringer Ingelheim and Eli Lilly. E.I. received research funding and honoraria for lectures from AstraZeneca, Tanabe Mitsubishi, Boehringer Ingelheim, Daiich Sankyo, Kyowa Kirin and Novo Nordisk. J.B.L. is a consultant for CSL and BioVie. P.K.T.L. received speaker’s honoraria from FibroGen, AstraZeneca and Baxter. B.D.M. is the National Leader of the ASCEND-D and ASCEND-ND trials of GlaxoSmithKline and the PROTECT and DUPLEX trials of Travere and is a steering committee member for the Novartis APPLAUSE trial and the Vera Therapeutics ATACICEPT trial. B.L.N. has received fees for advisory boards, scientific presentations, continuing education, steering committee roles and travel from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare, Janssen and Medscape, with all honoraria paid to his institution. R.D.P. received research support from Otsuka, Reata, Kadmon, Sanofi Genzyme and the US Department of Defense (TAME PKD); has been a member of steering committees for Sanofi Genzyme, Otsuka and TAME PKD, with fees paid to employing institutions; and has provided consultancy for Navitor, Palladiobio, Reata and Otsuka. G.R. has had consultancy agreements with Alexion Pharmaceuticals, Janssen, Akebia Therapeutics, Biocryst Pharmaceuticals, Menarini Ricerche SpA and AstraZeneca and speaker honoraria/travel reimbursement from Boehringer Ingelheim and Novartis. M.W. reports consulting fees from Amgen and Freeline, paid to him. H.J.L.H. received grant support from the NKF to his institute and is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Gilead, GoldFinch, Janssen, Merck, Novo Nordisk and Travere Pharmaceuticals. S.M., J.C., M.G., F.C.F., T.H.J., F.P.S., C.W. and J.F.M.W. have no conflicts to report associated with this manuscript.

Peer review

Peer review information

Nature Medicine thanks Jennifer Lees and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Jennifer Sargent, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1

Flow diagram of studies included in trial-level analyses.

Extended Data Fig. 2 Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the clinical endpoint.

Circles represent separate studies. Sizes are proportional to the number of events (kidney failure with replacement therapy, GFR <15 mL/min/1.73m2, or doubling of serum creatinine). Colors indicate intervention type. The black line is the line of regression through the studies. Blue lines show the 95% pointwise Bayesian prediction bands computed from the model. Red triangles indicate studies where the estimated treatment effects are beyond the margins.

Extended Data Fig. 3 Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the secondary clinical endpoint.

Circles represent separate studies. Sizes are proportional to the number of events (kidney failure with replacement therapy, GFR <15 mL/min/1.73m2). Colors indicate intervention type. The black line is the line of regression through the studies. Blue lines show the 95% pointwise Bayesian prediction bands computed from the model. Red triangles indicate studies where the estimated treatment effects are beyond the margins.

Extended Data Table 1 Categories of disease by intervention
Full size table
Extended Data Table 2 Mean slopes in treatment and control and treatment effect by intervention, causal disease and subgroups—total slope computed at 3 years, total slope computed at 2 years, chronic slope and acute slope
Full size table
Extended Data Table 3 Treatment effects on the clinical endpoint
Full size table
Extended Data Table 4 Trial-level analyses for the association between treatment effects on GFR slope over 2 years and treatment effects on the clinical endpoint by subgroups
Full size table
Extended Data Table 5 Trial-level results using secondary endpoint (that is, dialysis or GFR < 15 ml min−1 per 1.73 m2)
Full size table
Extended Data Table 6 Trial-level analyses for the association between treatment effects on GFR slope and treatment effects on the clinical endpoint by sensitivity excluding disease groups
Full size table
Extended Data Table 7 Application of GFR slope as surrogate endpoint in a new RCT: predicted treatment effect on clinical endpoint and PPV for subgroup-specific analyses
Full size table

Supplementary information

Supplementary Information

Supplementary Tables 1–11 and References.

Reporting Summary

Supplementary Data

Protocol

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inker, L.A., Collier, W., Greene, T. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med 29, 1867–1876 (2023). https://doi.org/10.1038/s41591-023-02418-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02418-0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing